Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3
3(60.0%)
Phase 2
1(20.0%)
Phase 1
1(20.0%)
5Total
Phase 3(3)
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06719141Phase 3Recruiting

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

Role: lead

NCT06660394Phase 3Recruiting

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

Role: lead

NCT06908226Phase 3Enrolling By Invitation

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

Role: lead

NCT05626634Phase 2Completed

Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

Role: lead

NCT06149663Unknown

Intermediate-Size Expanded Access Protocol (EAP) for LP352

Role: lead

NCT05364021Phase 1Completed

Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

Role: lead

All 6 trials loaded